Transgene receives patents covering homologous recombination technology in E. coli for fast generation of vectors.
Recombinant adenovirus vectors are a useful system for mammalian gene transfer, widely used in gene therapy, but also to study gene expression in vitro and in vivo. The potential applications for these vectors range from the study of gene functions to the production of high levels of recombinant proteins, recombinant vaccines and gene therapy. Generation of the recombinant adenoviral vectors is classically performed in eukaryotic cells, such as mammalian cells. However, these systems although they initially made vector generation possible, are strongly limited by their low efficiency.
The main feature of the method described in the patents consists of separately constructing the viral vector in bacterial systems and then producing the vector in the appropriate human complementation cell lines. Assembly of the complete viral genome occurs very rapidly in the prokaryotic host, thus allowing the entire process of virus generation and isolation to be completed within one month instead of several months by traditional methods.
Besides enabling Transgene to rapidly generate adenoviral vectors for its gene therapy programs, the technology has also already shown its usefulness in the field of functional genomics, for example in high throughput screening of gene functions.
"These new patents, combined with other intellectual properties covering both advanced defective adenoviral vectors and complementation cell lines, are yet again strengthening our leading position in the field of adenoviral vector technology," said Bernard Gilly, chief executive officer. "We will make the technology available for licenses to interested parties."
Transgene is a biopharmaceutical company dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired or inherited diseases for which there is no cure or adequate therapy at present. The company's proprietary technology platform consists of multiple vector families with a special emphasis on vaccinia virus, adenovirus, and synthetic vectors. Transgene has five products in clinical development to treat a variety of cancer indications, including two in phase II clinical trials and three in phase I clinical trials.
|Printer friendly Cite/link Email Feedback|
|Comment:||Transgene receives patents covering homologous recombination technology in E. coli for fast generation of vectors.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Oct 1, 2000|
|Previous Article:||GeNeuron announces issuance of United States patent.|
|Next Article:||Vertex Pharmaceuticals receives United States patent covering assay technology to accelerate drug discovery targeting hepatitis C protease.|